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Clinics 
Age and sex 
15 months old male patient. 
Previous history 
No preleukemia. No previous malignancy. No inborn 
condition of note. 
Organomegaly 
No hepatomegaly, no splenomegaly, no enlarged lymph 
nodes, no central nervous system involvement. 
Blood 
WBC : 50.2 (neutrophils 2%, lymphocytes 68%, 
probably blasts, monocytes 16%, atypical lymphocytes 
14% undifferenciated cells) X 109/l 
HB : 10.2g/dl 
Platelets : 191 X 109/l 
Blasts : 14% 
Bone marrow : The bone marrow was hypercellular 
with more than 50% blasts that were positive for CD45, 
CD33, CD15, CD13, CD14 and HLA-DR. 
Cyto-Pathology 
Classification 
Cytology: AML M4 
Immunophenotype: M4. CD13+,CD14+, CD15+, 
CD33+, CD45+, CD64+ and MPO. 
Diagnosis: Acute myelomonocytic leukemia. 
 
Survival 
Date of diagnosis: 02-2010 
Treatment: Chemotherapy (ADE) 
Complete remission was obtained. 
Treatment related death : no  
Relapse : no  
Status: Alive. Last follow up: 02-2011 
Survival: 12 months 
Karyotype 
Sample: BM 
Culture time: 24h 
Banding: G-band 
Karyotype at Relapse 
46,XY [5] / 46,Y,t(X;11)(q22;q23) [25] 
Other molecular cytogenetics technics 
Fluorescence in situ hybridization. 
Other molecular cytogenetics results 
MLL rearrangement was identified using the LSI MLL 
(11q23) Dual Color Break Apart Rearrangement probe 
(Abbott Molecular) revealing 80% of cells with MLL 
rearrangement. The rearrangement was confirmed in 
metaphases demonstrating that the distal part of the 
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Top: partial karyotype of the patient. Bottom: fluorescence in situ studies were performed successively on G-banded slides prepared for 
chromosome analysis using a locus-specific, break-apart probe for MLL (green and red signals) and with centromeric X/Y probe (Vysis) 
(red and green signal). Hybridization on metaphase cells with the MLL probe detected one MLL signal on the normal chromosome 11 
(red-green fusion signal) and signals on the der(11) (green signal) and the der(X), confirming MLL disruption. The red signal from MLL 
has moved to the derivative chromosome X, indicating that the breakpoint is in the 5' of the MLL gene. Arrows indicate derivative 
chromosomes, arrow heads are pointing to derivative chromosomes X and 11. 
 
Comments 
A previously healthy, 15 months-old boy presented 
with fever, and chest infection was diagnosed with 
acute myeloid leukemia FAB M4 in February 2010. 
His biochemistry was significant for GGT (8 IU/L; 
normal 9-40) and LDH 350 (normal 90-225). 
Chromosomal studies performed at diagnosis revealed 
the karyotype 46,Y,t(X;11)(q22;q23) in 25 out of 30
metaphases. Fluorescence in situ hybridization study 
showed rearrangement of the MLL gene in interphase 
and metaphase cells revealing that the break-apart 5'-
MLL segment is translocated to the derivative X 
chromosome. The patient achieved a complete 
hematological remission with chemotherapy one month 
later. Chromosomal and FISH studies performed in 
April, June, August and December confirmed the 
complete cytogenetic response without rearrangment of 
the MLL gene. He remains disease free 1 year from 
diagnosis. Our case together with the few reported 
similar cases suggest that chromosomal band Xq22 is a 
recurring 11q23 chromosomal partner in a subgroup of 
infant leukemia patients with AML.  
As the gene in Xq22 is yet unknown, it is therefore 
uncertain whether this translocation involve a new 
MLL partner. Due to the similar clinical features with 
patients with t(X;11)(q13;q23) involving the  
FOXO4/MLL genes, (such as occurrence in infants and 
young children diagnosed with acute myelomonocytic 
leukemia), the possibility of involvement of FOXO4 or 
FOXO related gene in our patient cannot be excluded. 
In addition as MLL rearrangements are frequently 
confirmed in cases with highly complex changes, 
complex and/or cryptic changes cannot be excluded. 
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